Clinical Trial Update: PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating PBF-1129 in combination with nivolumab for recurrent or metastatic non-small cell lung cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PBF-1129
• nivolumab (nivolumab)

Snippet

Sponsor: Dwight Owen | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Status: RECRUITING